← My Government dashboard

Government Watch

Dossier SCOTUS opinion 04-jun-2026
A decided U.S. Supreme Court ruling — binding legal precedent nationwide.

Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.

Key claim: The Supreme Court decided a dispute between generic maker Hikma and brand maker Amarin that determines legal limits on generic drug marketing and labeling relative to a branded product.

Abstract

U.S. Supreme Court opinion decided 2026-06-04, by Ketanji Brown Jackson.

Why this matters

The provided item is a U.S. Supreme Court opinion caption (Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.) and contains no biomedical research content on myeloproliferative neoplasms.

Source

Link

Briefing card

Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.
Stage: opinion · scotus · 04-jun-2026

The Supreme Court decided a dispute between generic maker Hikma and brand maker Amarin that determines legal limits on generic drug marketing and labeling relative to a branded product.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: scotus:10870060

Ask about this finding

Replies are grounded in the abstract and metadata above. The model will quote directly when possible and say so if a question isn't covered.

Stages other doctrine resolution introduced proposed rule passed chamber executive action final rule enacted district opinion circuit opinion opinion

Subscribe: calendar of upcoming dates · deadlines feed · all new records

build build 392 · ea9c128-dirty · 2026-08-09